Advertisement

Pharmacologic Therapy for Rhinitis and Allergic Eye Disease

  • Shan Shan Wu
  • Adi Cosic
  • Kathleen Gibbons
  • William Pender
  • Brian Peppers
  • Robert Hostoffer
Living reference work entry

Abstract

Allergic rhinitis and allergic eye disease affect the lives of many worldwide. They are Type I IgE-mediated hypersensitivity reactions. Allergic rhinitis occurs after sensitization of the mucosal lining of the nasal cavity to allergens. Likewise, allergic conjunctivitis occurs after sensitization of the ocular epithelium to allergens. Avoidance of allergens is the key in prevention of sensitization and the ensuing allergic responses. Various pharmacologic agents are developed to target the different underlying allergic mechanisms that cause the many symptoms of allergic rhinitis and allergic eye disease: antihistamines, mast cell stabilizers, anticholinergics, decongestants/vasoconstrictors, corticosteroids, multimodal anti-allergic agents, NSAIDs, and immunomodulators. Oral, intranasal, and topical formulations are available for certain agents. Complementary and alternative form of therapy can provide additional symptomatic relief. Furthermore, at the forefront of research for the treatment and management of allergic diseases including allergic rhinitis and allergic eye disease, allergen-specific immunotherapy with subcutaneous or sublingual immunotherapy can offer potential treatment and cure.

Keywords

Allergic rhinitis Allergic conjunctivitis Rhinitis Conjunctivitis Antihistamines Intranasal corticosteroids 

References

  1. Abelson MB, Paradis A, George MA, Smith LM, Maguire L, Burns R. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol. 1990;108(4):520–4.CrossRefGoogle Scholar
  2. Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016;7(1):52–67.CrossRefGoogle Scholar
  3. Arlian LG, Platts-Mills TA. The biology of dust mites and the remediation of mite allergens in allergic disease. J Allergy Clin Immunol. 2001;107(3 Suppl):S406–13.CrossRefGoogle Scholar
  4. Bielory BP, O’Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol. 2012;90(5):399–407.CrossRefGoogle Scholar
  5. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.CrossRefGoogle Scholar
  6. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.CrossRefGoogle Scholar
  7. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–1296.e3.CrossRefGoogle Scholar
  8. Calder VL, Jolly G, Hingorani M, Adamson P, Leonardi A, Secchi AG, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29(9):1214–22.CrossRefGoogle Scholar
  9. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–311.CrossRefGoogle Scholar
  10. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31(3):312–8.CrossRefGoogle Scholar
  11. Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol. 2014;70(3):569–75.CrossRefGoogle Scholar
  12. Chen Y-D, Jin X-Q, Yu M-H, Fang Y, Huang L-Q. Acupuncture for moderate to severe allergic rhinitis: a non-randomized controlled trial. Chin J Integr Med. 2016;22(7):518–24.CrossRefGoogle Scholar
  13. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.CrossRefGoogle Scholar
  14. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol. 2013;97(1):9–14.CrossRefGoogle Scholar
  15. Donshik PC. Contact lens chemistry and giant papillary conjunctivitis. Eye Contact Lens. 2003;29(1 Suppl):S37–9; discussion S57–9, S192–4.CrossRefGoogle Scholar
  16. Dvoracek JE, Yunginger JW, Kern EB, Hyatt RE, Gleich GJ. Induction of nasal late-phase reactions by insufflation of ragweed-pollen extract. J Allergy Clin Immunol. 1984;73(3):363–8.CrossRefGoogle Scholar
  17. Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013;9(1):16.CrossRefGoogle Scholar
  18. Erdinest N, Solomon A. Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol. 2014;14(5):457–63.CrossRefGoogle Scholar
  19. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123(4):455–64.CrossRefGoogle Scholar
  20. Fukuda K, Ohbayashi M, Morohoshi K, Zhang L, Liu F-T, Ono SJ. Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis. J Allergy Clin Immunol. 2009;124(4):827–33.e2.CrossRefGoogle Scholar
  21. Greenhawt M, Oppenheimer J, Nelson M, Nelson H, Lockey R, Lieberman P, et al. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. Ann Allergy Asthma Immunol. 2017;118(3):276–82.e2.CrossRefGoogle Scholar
  22. Greiner AN, Meltzer EO. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. Proc Am Thorac Soc. 2011;8(1):121–31.CrossRefGoogle Scholar
  23. Greiwe J, Bernstein JA. Nonallergic rhinitis: diagnosis. Immunol Allergy Clin North Am. 2016;36(2):289–303.CrossRefGoogle Scholar
  24. Gröger M, Klemens C, Wendt S, Becker S, Canis M, Havel M, et al. Mediators and cytokines in persistent allergic rhinitis and nonallergic rhinitis with eosinophilia syndrome. Int Arch Allergy Immunol. 2012;159(2):171–8.CrossRefGoogle Scholar
  25. Hendeles L. Selecting a decongestant. Pharmacotherapy. 1993;13(6 Pt 2):129S–34S; discussion 143S–6S.PubMedGoogle Scholar
  26. Hoyte FCL, Katial RK. Antihistamine therapy in allergic rhinitis. Immunol Allergy Clin North Am. 2011;31(3):509–43.CrossRefGoogle Scholar
  27. Jackson RT. Mechanism of action of some commonly used nasal drugs. Otolaryngol Head Neck Surg. 1991;104(4):433–40.CrossRefGoogle Scholar
  28. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33(5):1205–14.CrossRefGoogle Scholar
  29. Kaiser HB, Findlay SR, Georgitis JW, Grossman J, Ratner PH, Tinkelman DG, et al. The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated with perennial allergic rhinitis. Allergy Asthma Proc. 1998;19(1):23–9.CrossRefGoogle Scholar
  30. Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2009;103(5):373–80.CrossRefGoogle Scholar
  31. La Rosa M, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. 2013;39:18.CrossRefGoogle Scholar
  32. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy. 2006;36(6):777–84.CrossRefGoogle Scholar
  33. Leonardi A, Castegnaro A, Valerio ALG, Lazzarini D. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol. 2015;15(5):482–8.CrossRefGoogle Scholar
  34. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489–98.CrossRefGoogle Scholar
  35. Maiti R, Jaida J, Rahman J, Gaddam R, Palani A. Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: a comparative study of efficacy and safety. J Pharmacol Pharmacother. 2011;2(4):270–6.CrossRefGoogle Scholar
  36. Masferrer JL, Kulkarni PS. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Surv Ophthalmol. 1997;41(Suppl 2):S35–40.CrossRefGoogle Scholar
  37. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy. 1997;52(36 Suppl):33–40.CrossRefGoogle Scholar
  38. Méndez-Sánchez R, González-Iglesias J, Puente-González AS, Sánchez-Sánchez JL, Puentedura EJ, Fernández-de-Las-Peñas C. Effects of manual therapy on craniofacial pain in patients with chronic rhinosinusitis: a case series. J Manipulative Physiol Ther. 2012;35(1):64–72.CrossRefGoogle Scholar
  39. Moore EJ, Kern EB. Atrophic rhinitis: a review of 242 cases. Am J Rhinol. 2001;15(6):355–61.CrossRefGoogle Scholar
  40. Morris S, Eccles R, Martez SJ, Riker DK, Witek TJ. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Am J Rhinol. 1997;11(2):109–15.CrossRefGoogle Scholar
  41. Mortuaire G, de Gabory L, François M, Massé G, Bloch F, Brion N, et al. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137–44.CrossRefGoogle Scholar
  42. Nelson HS. Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient. Expert Rev Clin Pharmacol. 2016;11:1443–1451.CrossRefGoogle Scholar
  43. Prussin C, Metcalfe DD. 5.IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006;117(2):S450–S456.CrossRefGoogle Scholar
  44. Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring). 2010;18(12):2398–400.CrossRefGoogle Scholar
  45. Shah SR, Miller C, Pethick N, Uryniak T, Jones MKC, O’Dowd L. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther. 2003;25(8):2198–214.CrossRefGoogle Scholar
  46. Shi S-J, Platts SH, Ziegler MG, Meck JV. Effects of promethazine and midodrine on orthostatic tolerance. Aviat Space Environ Med. 2011;82(1):9–12.CrossRefGoogle Scholar
  47. Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–17.CrossRefGoogle Scholar
  48. Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94(1):134–6.CrossRefGoogle Scholar
  49. Stillerman A, Nachtsheim C, Li W, Albrecht M, Waldman J. Efficacy of a novel air filtration pillow for avoidance of perennial allergens in symptomatic adults. Ann Allergy Asthma Immunol. 2010;104(5):440–9.CrossRefGoogle Scholar
  50. Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J, Georges G. Evaluation of patients’ preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg. 2004;131(3):225–31.CrossRefGoogle Scholar
  51. Sublett JW, Bernstein DI. Occupational rhinitis. Immunol Allergy Clin North Am. 2011;31(4):787–96, vii.CrossRefGoogle Scholar
  52. Timmerman H. Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy. 2000;55(Suppl 60):5–10.CrossRefGoogle Scholar
  53. Toohill RJ, Lehman RH, Grossman TW, Belson TP. Rhinitis medicamentosa. Laryngoscope. 1981;91(10):1614–21.CrossRefGoogle Scholar
  54. Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol. 1989;84(4 Pt 1):492–501.CrossRefGoogle Scholar
  55. Wallace DV, Dykewicz MS. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol. 2008;122(2):S1–84.CrossRefGoogle Scholar
  56. Welch D, Ousler GW, Nally LA, Abelson MB, Wilcox KA. Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. Adv Exp Med Biol. 2002;506(Pt B):1051–5.CrossRefGoogle Scholar
  57. Wilkinson J, Faleiro R. Acupuncture in pain management. Contin Educ Anaesth Crit Care Pain. 2007;7(4):135–8.CrossRefGoogle Scholar
  58. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–82.CrossRefGoogle Scholar
  59. Zhou F, Yan L-J, Yang G-Y, Liu J-P. Acupoint herbal patching for allergic rhinitis: a systematic review and meta-analysis of randomised controlled trials. Clin Otolaryngol. 2015;40(6):551–68.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Shan Shan Wu
    • 1
  • Adi Cosic
    • 2
  • Kathleen Gibbons
    • 3
  • William Pender
    • 4
  • Brian Peppers
    • 5
  • Robert Hostoffer
    • 6
  1. 1.University Hospitals Cleveland Medical CenterClevelandUSA
  2. 2.Lake Erie College of Osteopathic MedicineLake ErieUSA
  3. 3.University Hospitals Regional HospitalsTraditional Rotating Internship Residency ProgramRichmond HeightsUSA
  4. 4.Ohio University Heritage College of Osteopathic MedicineWarrensville HeightsUSA
  5. 5.University Hospitals Regional HospitalsAllergy-Immunology Fellowship ProgramRichmond HeightsUSA
  6. 6.Allergy/Immunology Associates, Inc.Mayfield HeightsUSA

Section editors and affiliations

  • Timothy Craig
    • 1
  • Dennis K. Ledford
    • 2
  1. 1.Department of Medicine and PediatricsPenn State College of MedicineHersheyUSA
  2. 2.Division of Allergy & Immunology, Dept. of Internal MedicineUniversity of South Florida Morsani College of Medicine, James A Haley Veterans' Hospital, Asthma and Immunology Associates of Tampa BayTampaUSA

Personalised recommendations